1997 Fiscal Year Final Research Report Summary
Establishment of a recurrent spontaneous abortion mouse model by intrauterine immunization and development of a new treatment
| Project/Area Number |
08671855
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
YAMADA Hideto Hokkaido Univ., Medical Hospital., Instructor, 医学部・附属病院, 助手 (40220397)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OKUYAMA Kazuhiko Hokkaido Univ., Medical Hospital., Instructor, 医学部・附属病院, 助手 (40214085)
FUJINO Takafumi Hokkaido Univ., Fac.of Med., Lecturer, 医学部, 講師 (20209076)
|
|---|
| Project Period (FY) |
1996 – 1997
|
| Keywords | Recurrent spontaneous abortion / Immunoglobulin / Antiphospholipid synbrom |
|---|
| Research Abstract |
The aim of this study is to investigate the efficacy of massive intravenous immunoglobulin (MIVIg) treatment for women with a history of recurrent spontaneous abortion (RSA) due to unexplained etiology. Subjects consisted of 9 women and 11 pregnancies having history of 4 or more consecutive RSA with unexplained etiology and no live births. Mean number of fetal losses is 4.5 (ranged from 4 to 6 abortions). Over the course of 5 days, at 20 g/day, immunoglobulin has been infused intravenously duning 4-7 gestational week (GW). No additional infusion has been performed. Two pregnancies resulted in missed abortions at 6 and 7GW,respectively. Mosaicism (46XX/48XX,+16, +20), and tetraploidy (92XXXX) were found by chromosome analyzes of the two abortus. Eight out of the other 9 pregnancies resulted in full term deliveries of healthy neonates. One pregnancy developed an intrauterine growth retardation and fetal distress, resulting in a premature delivery (30GW) by cesarean section. Thus, excluding the 2 abortions with chromosome aberrations, the MIVIg treatment was effective in all 9 pregnancies of RSA women with unexplained etiology. This MIVIg treatment (100g administered in early gestation) may be a benefical alternative to previous IVIg infusion methods and should be evaluated in further studies employing a larger number of homogeneous patients who fall into a high risk catagory of first trimester abortions.
|
Research Products
(8 results)
